Randomized, Double-blind, Active-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of GC3111 in Healthy Adults
Latest Information Update: 07 Jan 2022
At a glance
- Drugs GC 3111 (Primary) ; DTaP vaccine
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GC Biopharma
- 27 Jan 2020 New trial record